OREXINS - Orexins / hypocretins - new targets for therapeutic control of feeding and sleeping disorders (OREXINS) (LIFE QUALITY) (2002-09-01 - 2005-08-31) (»add to infobox)

N. N. HEINRICH-HEINE-UNIVERSITAET DUESSELDORF, N. N. GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD, N. N. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, N. N. UNIVERSITY OF LIVERPOOL, N. N. UPPSALA UNIVERSITET

HEINRICH-HEINE-UNIVERSITAET DUESSELDORF (DEA11 - Düsseldorf, Kreisfreie Stadt) (Germany), GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD (UK540 - Essex) (Great Britain), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR716 - Rhône) (France), UNIVERSITY OF LIVERPOOL (UK840 - Merseyside) (Great Britain), UPPSALA UNIVERSITET (SE021 - Uppsala län) (Sweden)

Since their discovery in 1998 two peptides named origins (synonym hypo cretins) receive much attention because of their central role in the regulation of basic body functions: food intake, energy balance and the sleep waking cycle. Loss of the origin containing neurons in the hypothalamus, which project widely in the brain, is the cause of human narcolepsy, a disabling disorder of vigilance, which also occurs in dogs where the G-protein coupled origin receptors are missing. Understanding the functions of this central command system on the molecular, cellular, network, behaviour and clinical levels is necessary for a rational therapeutic approach to disorders of feeding and sleeping. Our consortium representing molecular biology, physiology, pharmacology, biological psychology, clinical medicine and the pharmaceutical industry will take this task.

PERSONS (5/5)

RELATED NAVIGATION AREA(S) (2/2)